Literature DB >> 15276554

Regression of severe pulmonary arteriovenous malformations after Fontan revision and "hepatic factor" rerouting.

Nancy A Pike1, Luca A Vricella, Jeffrey A Feinstein, Michael D Black, Bruce A Reitz.   

Abstract

Although previously described in patients undergoing staged palliation for univentricular heart disease, the mechanism by which hepatic venous flow prevents development of pulmonary arteriovenous malformations is still not completely understood. We present a case in which successful H-type Fontan revision with rerouting of hepatic venous flow through a hemiazygous vein successfully reversed the progression of severe left pulmonary arteriovenous malformations.

Entities:  

Mesh:

Year:  2004        PMID: 15276554     DOI: 10.1016/j.athoracsur.2004.02.003

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  28 in total

Review 1.  Patient-Specific Modeling of Hemodynamics: Supporting Surgical Planning in a Fontan Circulation Correction.

Authors:  Theodorus M J van Bakel; Kevin D Lau; Jennifer Hirsch-Romano; Santi Trimarchi; Adam L Dorfman; C Alberto Figueroa
Journal:  J Cardiovasc Transl Res       Date:  2018-01-08       Impact factor: 4.132

2.  Experimental Investigation of the Effect of Non-Newtonian Behavior of Blood Flow in the Fontan Circulation.

Authors:  Andrew L Cheng; Niema M Pahlevan; Derek G Rinderknecht; John C Wood; Morteza Gharib
Journal:  Eur J Mech B Fluids       Date:  2017-12-27       Impact factor: 2.183

3.  Hemodynamic study of TCPC using in vivo and in vitro 4D Flow MRI and numerical simulation.

Authors:  Alejandro Roldán-Alzate; Sylvana García-Rodríguez; Petros V Anagnostopoulos; Shardha Srinivasan; Oliver Wieben; Christopher J François
Journal:  J Biomech       Date:  2015-03-19       Impact factor: 2.712

4.  Pulmonary hepatic flow distribution in total cavopulmonary connections: extracardiac versus intracardiac.

Authors:  Lakshmi P Dasi; Kevin Whitehead; Kerem Pekkan; Diane de Zelicourt; Kartik Sundareswaran; Kirk Kanter; Mark A Fogel; Ajit P Yoganathan
Journal:  J Thorac Cardiovasc Surg       Date:  2011-01       Impact factor: 5.209

5.  Surgical planning of the total cavopulmonary connection: robustness analysis.

Authors:  Maria Restrepo; Mark Luffel; Jake Sebring; Kirk Kanter; Pedro Del Nido; Alessandro Veneziani; Jarek Rossignac; Ajit Yoganathan
Journal:  Ann Biomed Eng       Date:  2014-10-15       Impact factor: 3.934

6.  Virtual surgical planning, flow simulation, and 3-dimensional electrospinning of patient-specific grafts to optimize Fontan hemodynamics.

Authors:  Dominik Siallagan; Yue-Hin Loke; Laura Olivieri; Justin Opfermann; Chin Siang Ong; Diane de Zélicourt; Anastasios Petrou; Marianne Schmid Daners; Vartan Kurtcuoglu; Mirko Meboldt; Kevin Nelson; Luca Vricella; Jed Johnson; Narutoshi Hibino; Axel Krieger
Journal:  J Thorac Cardiovasc Surg       Date:  2017-12-05       Impact factor: 5.209

7.  Imaging and patient-specific simulations for the Fontan surgery: current methodologies and clinical applications.

Authors:  Diane A de Zélicourt; Alison Marsden; Mark A Fogel; Ajit P Yoganathan
Journal:  Prog Pediatr Cardiol       Date:  2010-12-01

8.  Can time-averaged flow boundary conditions be used to meet the clinical timeline for Fontan surgical planning?

Authors:  Zhenglun Alan Wei; Phillip M Trusty; Mike Tree; Christopher M Haggerty; Elaine Tang; Mark Fogel; Ajit P Yoganathan
Journal:  J Biomech       Date:  2016-11-10       Impact factor: 2.712

9.  Recent advances in the application of computational mechanics to the diagnosis and treatment of cardiovascular disease.

Authors:  Juan C Del Alamo; Alison L Marsden; Juan C Lasheras
Journal:  Rev Esp Cardiol       Date:  2009-07       Impact factor: 4.753

10.  Numerical and experimental investigation of pulsatile hemodynamics in the total cavopulmonary connection.

Authors:  Elaine Tang; Christopher M Haggerty; Reza H Khiabani; Diane de Zélicourt; Jessica Kanter; Fotis Sotiropoulos; Mark A Fogel; Ajit P Yoganathan
Journal:  J Biomech       Date:  2012-11-30       Impact factor: 2.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.